Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in...
October 6, 2026
Share
Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial.